Intrexon Corporation
Intrexon Corporation is developing DNA control systems to enhance the safety and efficacy of existing and novel biological therapeutics. The company's technology employs special genetic components and activator compounds to tightly control the delivery, targeting, activation, regulation and location of biologics. The goal of such DNA-mediated control is to improve the safety of those biologics while extending their clinical effectiveness. The company is currently engaged in clinical and pre-clinical studies related to solid tumor cancers and other intractable diseases that must be addressed with powerful biotherapeutic strategies. Together with its partners, Intrexon is committed to improving safety and clinical outcomes through the use of controllable biotherapeutics. For more information, please visit www.dna.com.
Pinnacle Pharmaceuticals
Pinnacle Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development of novel therapies in areas of significant unmet medical need. Pinnacle develops critical-care therapeutics for antibacterial, oncology, and pain management indications by leveraging its supramolecular chemistry platform and drug formulation expertise. Additionally, Pinnacle is advancing novel and potent synergistic compounds for current antibiotic regimes to treat patients suffering from infections refractory to the current gold-standard. Pinnacle is pursuing therapeutics for several infectious disease indications including methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE). Pinnacle is rapidly progressing its lead compounds from the research laboratory into clinical development. For more information, please visit www.pinnaclepharmaceuticals.com